Drug intelligence / Profile preview

F-102

Development stage: Discontinued
Lead developer: Fera
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Ophthalmic

Overview

F-102 is an ophthalmic drug candidate being developed by Fera Pharmaceuticals. It is a hydrocortisone-based formulation, specifically an ointment, intended for the treatment of various eye diseases. Hydrocortisone is a corticosteroid that acts as an anti-inflammatory agent by binding to glucocorticoid receptors, thereby reducing the production of inflammatory mediators. While a Phase 2 clinical trial for allergic conjunctivitis was terminated, the program has received Orphan Drug designation and is currently in early development or preclinical stages for broader ophthalmic indications.

Other names: hydrocortisone ophthalmic ointment

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on F-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-102.

Explore the full profile